Marinus Pharmaceuticals, Inc
MRNS
MRNS was delisted on the 10th of February, 2025.
77 hedge funds and large institutions have $312M invested in Marinus Pharmaceuticals, Inc in 2020 Q3 according to their latest regulatory filings, with 11 funds opening new positions, 39 increasing their positions, 20 reducing their positions, and 28 closing their positions.
95% more repeat investments, than reductions
Existing positions increased: 39 | Existing positions reduced: 20
92% more call options, than puts
Call options by funds: $23.2M | Put options by funds: $12.1M
35% more capital invested
Capital invested by funds: $231M → $312M (+$80.5M)
18% less funds holding
Funds holding: 94 → 77 (-17)
33% less funds holding in top 10
Funds holding in top 10: 3 → 2 (-1)
61% less first-time investments, than exits
New positions opened: 11 | Existing positions closed: 28
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
6CM
683 Capital Management
New York
|
+$6.39M |
| 2 |
MS
Maven Securities
St Helier,
Jersey
|
+$2.85M |
| 3 |
BlackRock
New York
|
+$2.46M |
| 4 |
SCM
Suvretta Capital Management
New York
|
+$2.41M |
| 5 |
Alyeska Investment Group
Chicago,
Illinois
|
+$1.98M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
WG
Winton Group
London,
United Kingdom
|
-$3.03M |
| 2 |
VA
VR Adviser
New York
|
-$2.06M |
| 3 |
MIM
Monashee Investment Management
Boston,
Massachusetts
|
-$2.04M |
| 4 |
ACM
Asymmetry Capital Management
San Francisco,
California
|
-$1.49M |
| 5 |
D.E. Shaw & Co
New York
|
-$1.21M |
MRNS Hedge Fund Activity: Q3 2020 in Review
77 of the 4,970 institutional investors tracked by Wall St. Rank reported a position in Marinus Pharmaceuticals, Inc (MRNS) for Q3 2020, worth a combined $312M — up 35% from $231M a quarter earlier.
Sellers outnumbered buyers: 28 funds closed out of MRNS and 11 opened new positions — a net loss of 17 holders — while 20 trimmed existing stakes and 39 added.
The largest buyer was 683 Capital Management, adding an estimated $6.39M. The largest seller was Winton Group, exiting entirely with an estimated $3.03M sold.
- 77 institutional investors held Marinus Pharmaceuticals, Inc (MRNS) as of Q3 2020, down from 94 in Q2 2020.
- Funds reported $312M of Marinus Pharmaceuticals, Inc stock for Q3 2020, up 35% quarter-over-quarter.
- 11 funds opened new Marinus Pharmaceuticals, Inc positions in Q3 2020 and 28 closed out, a net change of -17 holders.
- The largest Marinus Pharmaceuticals, Inc buyer in Q3 2020 was 683 Capital Management, an estimated $6.39M added.
- The largest Marinus Pharmaceuticals, Inc seller in Q3 2020 was Winton Group, an estimated $3.03M sold.
Based on aggregated 13F filings for Q3 2020.